APA (7th ed.) Citation

Hooper, P. B., Farberg, A. S., Fitzgerald, A. L., Siegel, J. J., Rackley, B. B., Prasai, A., . . . Litchman, G. H. (2022). Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. Cancer Investigation, 40(10), 911. https://doi.org/10.1080/07357907.2022.2116454

Chicago Style (17th ed.) Citation

Hooper, Perry B., Aaron S. Farberg, Alison L. Fitzgerald, Jennifer J. Siegel, Briana B. Rackley, Anesh Prasai, Sarah J. Kurley, Matthew S. Goldberg, and Graham H. Litchman. "Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients." Cancer Investigation 40, no. 10 (2022): 911. https://doi.org/10.1080/07357907.2022.2116454.

MLA (9th ed.) Citation

Hooper, Perry B., et al. "Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients." Cancer Investigation, vol. 40, no. 10, 2022, p. 911, https://doi.org/10.1080/07357907.2022.2116454.